Work

60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(23)00260-5

Authors: J. Neal, N. Pavlakis, S-W. Kim, Y. Goto, S.M. Lim, G. Mountzios, E. Fountzilas, A. Mochalova, D.C.C. Christoph, A. Bearz, X. Quantin, R. Palmero, V. Antic, E. Chun, T. Rao Edubilli, Y-C. Lin, M. Huseni, C. Scheffold, P. Vervaet, T. Newsom-Davis

Institutions: Stanford Cancer Institute, Stanford University, The University of Sydney, Royal North Shore Hospital, Asan Medical Center, Yonsei University, Yonsei University Health System, Henry Dunant Hospital, Euromedica, Kliniken Essen-Mitte, Centro di Riferimento Oncologico, Université de Montpellier, Institut Català d'Oncologia, F. Hoffmann-La Roche AG, Genentech, Roche (United Kingdom), Exelixis (United States), Chelsea and Westminster Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, Regeneron Pharmaceuticals, Exelixis, Genentech

OpenAlex ID: W4362586757

FWCI: 4.563

Cites:

Cited by: 29

Related to: 10